22nd Century Group (NASDAQ:XXII), a leading agricultural biotechnology company dedicated to tobacco harm reduction and reduced-nicotine tobacco, today reported its financial results for the fourth quarter and full year ended December 31, 2025.
For the full year 2025, 22nd Century Group reported net revenues of $17.6 million, with $3.5 million generated in the fourth quarter.
The company recorded a net loss from continuing operations of $13.1 million for the year, which narrowed to $2.8 million in the fourth quarter.
This improvement in the quarterly bottom line reflects the successful execution of a comprehensive cost-reduction initiative implemented earlier in the fiscal year.
A major milestone of the 2025 fiscal year was the transformation of the company’s balance sheet.
22nd Century Group exited the year entirely debt-free, having eliminated more than $8 million in legacy debt obligations.
This was made possible by the successful recovery of a $9.5 million insurance settlement.
As of December 31, 2025, the company maintained a cash position of $7.1 million, providing a stable foundation for its 2026 commercial operations.
On the operational front, the company significantly expanded the market presence of its flagship VLN® (Very Low Nicotine) products.
Throughout 2025, 22nd Century Group secured new retail and state authorizations across multiple partner brands, increasing the availability of the only combustible cigarette to receive a "Modified Risk Tobacco Product" (MRTP) authorization from the FDA.